Thus, partial suppression of BACE1 attenuates Aβ generation and AD-related pathology (Kimura et al., 2010), suggesting that partial inhibition of BACE1 could be an ideal target for AD treatment. The gene discussed is BACE1; the disease is Alzheimer disease.